Disclosure under Regulation 30 of SEBI Listing Regulations.

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹375.00

prior close

₹380.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%+0.1% vs market

Pharmaceuticals peers, median of 150sector-1.5%+0.6% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.5

15m

-0.6

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9-1.0+0.1-1.5+0.6

Next day

-2.7-1.3-1.4-2.0-0.7

-4.5-3.1-1.5-3.5-1.1

-4.0-2.8-1.2-2.8-1.2

-5.0-2.5-2.4-2.8-2.1

-2.3-2.1-0.3-2.3-0.0

-4.0-0.2-3.8-1.5-2.5

15d

-8.1+1.0-9.1-0.4-7.7

-6.1+3.5-9.7+2.3-8.4

-31.3-1.9-29.4-4.0-27.3

-28.5+1.4-29.8-1.8-26.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Hikal Limited has received the Good Manufacturing Practices (GMP) certificate from ANVISA, Brazil's health regulatory agency, for its Jigani manufacturing unit in Bengaluru. The ANVISA audit was conducted from April 14 to April 18, 2025, and covered multiple Active Pharmaceutical Ingredients (APIs). This certification enables the company to manufacture and supply pharmaceutical inputs for the Brazilian market. The Jigani unit is a key pharmaceutical manufacturing facility for Hikal.

Likely market impact

This is a positive development for Hikal as the ANVISA GMP certification opens up the Brazilian pharmaceutical market for the company's API products, potentially adding a new revenue stream. Brazil is one of the largest pharmaceutical markets in Latin America, and this approval strengthens Hikal's global regulatory footprint.